Over 1,500 US startups raised USD34.2 billion in venture capital (CV) funding during the first quarter of 2024. However, the latest GlobalData research reveals that this represented a year-on-year (YoY) decline in both deals volume and value.
In the last quarter, 1,527 funding deals were announced, compared to 2,922 VC deals announced during January- April 2023. The total disclosed funding value of these 2023 deals stood at USD47.9 billion. GlobalData says the latest quarterly figures represent a YoY deal volume decrease of 47.7% and a value decline of 28.7%.
“Market volatility seems to have impacted investors’ confidence in VC funding deal-making activity in the US,” said GlobalData Lead Analyst Aurojyoti Bose. “However, despite the decline, the US continued to lead the global VC funding landscape in terms of deals volume as well as value.”
The US had a 28% share of the total number of VC funding deals announced globally during January-April 2024, while the country’s share of the corresponding disclosed funding value stood at 45.2%.
“Despite the market volatility, the US remains attractive to VC investors, which is also evident from the fact that it accounted for close to half of total venture capital raised globally during the review period,” added Bose.
Some of the notable VC funding deals announced in the US during January-April 2024 include the USD1 billion raised by Xaira Therapeutics, USD700 million raised by Wonder, USD675 million raised by Figure AI, USD520 million raised by Nexamp and USD400 million raised by Mirador Therapeutics.
